Akt/ERK Inhibitor ONC201

DRUG5 trials

Sponsors

M.D. Anderson Cancer Center, University of Wisconsin, Madison, Ira Winer, Jonsson Comprehensive Cancer Center

Conditions

Central Nervous System LymphomaGastric Mantle Cell LymphomaMalignant Ovarian Epithelial TumorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia

Phase 1

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

TerminatedNCT02392572

M.D. Anderson Cancer CenterRecurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome +3

Start: 2015-11-03End: 2026-08-14Updated: 2026-08-20

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

TerminatedNCT02420795

M.D. Anderson Cancer CenterCentral Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma +4

Start: 2015-11-03End: 2020-11-16Updated: 2022-04-04

ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

WithdrawnNCT04854044

Jonsson Comprehensive Cancer CenterRecurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma +1

Start: 2021-05-01End: 2026-07-01Updated: 2021-05-12

Phase 2

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

TerminatedNCT03733119

University of Wisconsin, MadisonTriple Negative Breast Cancer

Start: 2018-11-13End: 2021-02-13Updated: 2022-03-10

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

RecruitingNCT04055649

Ira WinerMalignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma +7

Start: 2020-01-21End: 2027-05-28Target: 62Updated: 2026-06-17

Related Papers

A whole food, plant-based diet reduces amino acid levels in patients with metastatic breast cancer.

2024-12-192 citations

Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.

2022-04-12102 citations

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Journal for ImmunoTherapy of Cancer2019-05-2270 citations

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

Blood2017-12-07

Abstract 3012: ONC201 induces cell death in triple negative, BRCA1-deficient and non-triple negative breast cancer cells

Cancer Research2016-07-15

Abstract 3309: Novel small molecule ONC201 induces cell death and targets chemotherapy-resistant cancer stem-like cells in triple negative breast cancer

Cancer Research2016-07-15

Abstract 3087: Combination of ONC201 and bevacizumab significantly impacts colorectal cancer growth and metastasis <i>in vivo</i>

Cancer Research2016-07-15

Abstract 349: Structure-activity relationships and mechanistic analysis of analogues of the clinical-stage anti-cancer small molecule ONC201

Cancer Research2016-07-15

First-in-class small molecule ONC201 in b-cell malignancies.

Journal of Clinical Oncology2016-05-20